Mainz / Düsseldorf - At the world’s biggest trade show for medical technology MEDICA commencing on 12th of November, ORGENTEC joins over 4500 other international exhibitors displaying latest projects and innovations. Therefore, we may give you an update on ORGENTEC’s most recent product developments!
Calprotectin by ORGENTEC – now also available for ELISA:
The Calprotectin ELISA (ORG 580) completes the gastroenterology portfolio beside the existing product range for autoimmune and infectious disease diagnostics and the automated Calprotectin test on Alegria® (ORG 280).
As an ideal marker for differentiation between intestinal inflammation and irritable bowel syndrome (IBS), Calprotectin serves as a simple, non-invasive test that can be reasonably be carried out before any imaging or endoscopy. Especially children or pregnant women with elevated CRP or indeterminate blood picture, respectively, may benefit from a method with no adverse effects.
Since inflammatory bowel diseases (IBD) are increasing, there is an increasing demand for the detection of calprotectin as a marker of inflammation in stool samples. This need is likely to increase due to new NICE guidelines*, incorporating Calprotectin as a key diagnostics marker for the differentiation between IBD and IBS.
In a nutshell, Calprotectin in the stool is an accurate, noninvasive early marker of inflammatory bowel disease - concentrations correlate with disease activity in ulcerative colitis and Crohn’s disease. They decline with response to therapy, and increasing calprotectin levels may indicate relapses even before clinical symptoms become evident. Similarly, the calprotectin measurement is used to monitor therapy, because the measured value in µg/g calprotectin corresponds to the strength of the inflammation. About 50 µg/g calprotectin indicate a morbidly increased calprotectin concentration.
About Orgentec
Orgentec offers a portfolio of more than 300 tests, primarily enzyme-linked immunosorbent assays (ELISA), that help diagnose rheumatology, thrombosis and gastroenterology disorders, as well as infectious diseases. It also offers a fully automated instrument and associated test kits that enable laboratories to complete multiple assays and deliver faster results than traditional ELISA tests. Orgentec has a well-established position in Europe and a growing presence in Asia, Latin America and the Middle East. Orgentec is a company of Water Street Healthcare Partners, a strategic investor focused exclusively on the health care industry. For more information, visit www.orgentec.com.